IRLA · IRulya Therapeutics Inc. · Held by Funds
Substantial doubt about the company's ability to continue as a going concern.
“Factoring in these potential cash payments, based on its current operating plan, the Company believes that its cash and cash equivalents balance will not be sufficient to fund operations and capital expenditures for at least the twelve months following the issuance of these unaudited condensed consolidated financial statements. Accordingly, the Company concluded that substantial doubt about the Company's ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.”View the 10-Q filed Aug 14, 2026
Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this exact listed security, matched by CUSIP. Each row is one fund position with its size, value and weight in that fund.
Fund Ownership of IRLA by Fund Type
Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026Index funds and index ETFs hold 1.18% of shares outstanding.
| Fund type | Of shares outstanding | Shares |
|---|---|---|
| Index funds | 0.00% | 0 |
| Index ETFs | 1.18% | 12,044 |
| Active ETFs | 0.00% | 0 |
| Active funds | 0.00% | 1 |
| Unclassified | 0.00% | 0 |
| All registered funds | 1.18% | 12,045 |
How fund types are measured
Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.
Funds holding IRLA
4 fund positions| Fund | Ticker | Balance | Value | % of Fund | Side | Reported | Open |
|---|---|---|---|---|---|---|---|
| Invesco DWA NASDAQ Momentum ETF | — | 5,710 | $268,313 | 0.53% | Long | 2020-01-31 | |
| Defiance Nasdaq Junior Biotechnology ETF | — | 680 | $62,329 | 0.86% | Long | 2021-09-30 | |
| iShares Evolved U.S. Innovative Healthcare ETF | — | 391 | $762 | 0.00% | Long | 2022-07-31 | |
| Guggenheim Active Allocation Fund | GUG | 11 | $13 | 0.00% | Long | 2026-05-29 |